The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients

Diabetes, Obesity and Metabolism

Volumn 14, Issue 6, 2012, Pages 518-522

  Fadini, G P ^a,b   Albiero, M ^a,b   Menegazzo, L ^a,b   De Kreutzenberg, S V ^a,b   Avogaro, A ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Cardiovascular disease; Diabetes; Diabetes complications; Diabetes mellitus; Stem cells

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHROMOGENIC SUBSTRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; FLUORINE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

EID: 84860252744     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01550.x     Document Type: Article

References (21)

1. Charbonnel B, Cariou B. Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. Diabetes Obes Metab 2011; 13: 99-117.
2. Meier JJ, Gethmann A, Gotze O et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 49: 452-458.
3. Ryskjaer J, Deacon CF, Carr RD et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485-493.
4. Han SJ, Kim HJ, Choi SE et al. Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 89: e49-e52.
5. Firneisz G, Varga T, Lengyel G et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010; 5: e12226.
6. Hjollund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 2010; 54: 2206-2208.
7. Waget A, Cabou C, Masseboeuf M et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 2010; 152: 3018-3029.
8. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004; 324: 92-97.
9. Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 2011; 60: 52-56.
10. Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in Type 2 diabetes. Diabet Med 2009; 26: 649-654.
11. Lindsay JR, Duffy NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005; 22: 654-657.
12. Fadini GP, de Kreutzenberg SV, Mariano V et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab 2011; 13: 718-725.
13. Roy S, Khanna V, Mittra S et al. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice. Life Sci 2007; 81: 72-79.
14. Fadini GP, Boscaro E, Albiero M et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-1609.
15. Thompson NL, Hixson DC, Callanan H et al. A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. Biochem J 1991; 273(Pt 3): 497-502.
16. Erickson RH, Suzuki Y, Sedlmayer A, Kim YS. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. J Biol Chem 1992; 267: 21623-21629.
17. Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-1172.
18. McKillop AM, Duffy NA, Lindsay JR et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008; 79: 79-85.
19. Gu N, Tsuda M, Matsunaga T et al. Glucose regulation of dipeptidyl peptidase IV gene expression is mediated by hepatocyte nuclear factor-1alpha in epithelial intestinal cells. Clin Exp Pharmacol Physiol 2008; 35: 1433-1439.
20. Alam ML, Van der Schueren BJ, Ahren B et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 378-381.
21. Lamers D, Famulla S, Wronkowitz N et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-1925.